Item 8.01Other Events.
On January 29, 2021, Turning Point Therapeutics, Inc. (the "Company") issued a
press release providing program updates, including reporting updated interim
data from the registrational Phase 2 TRIDENT-1 study of the Company's lead drug
candidate repotrectinib, in patients with ROS1-positive, tyrosine kinase naïve,
non-small cell lung cancer. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release issued by Turning Point Therapeutics, Inc. on January 29,
2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses